21:43 , Oct 27, 2017 |  BC Week In Review  |  Company News

Arcturus, JNJ to develop nucleic acids to treat HBV

Arcturus Therapeutics Inc. (San Diego, Calif.) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize nucleic acid-based compounds to treat HBV. The companies will use Arcturus' unlocked nucleomonomer...
21:09 , Sep 15, 2017 |  BC Week In Review  |  Company News

J&J drops Achillion HCV deal

Johnson & Johnson (NYSE:JNJ) terminated a 2015 deal with Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) to develop and commercialize HCV therapies, including triplet therapy JNJ-4178 . J&J said it decided to discontinue development of JNJ-4178 “in light...
00:12 , Sep 12, 2017 |  BC Extra  |  Company News

Achillion down after J&J drops HCV compound

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) lost $1.08 (22%) to $3.83 Monday after Johnson & Johnson (NYSE:JNJ) terminated a 2015 deal to develop and commercialize HCV therapies, including triplet therapy JNJ-4178 . J&J said it decided to...
01:42 , Dec 30, 2016 |  BC Week In Review  |  Clinical News

JNJ-4178: Ph IIb OMEGA-1 started

Achillion said Johnson & Johnson began the open-label, international Phase IIb OMEGA-1 trial to evaluate oral JNJ-4178 once daily for 6 or 8 weeks in about 300 patients without cirrhosis. JNJ-4178 comprises 800 mg AL-335...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

AL-335: Interim Phase IIa data

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN, New Haven, Conn.) reported interim data from 4 cohorts of treatment-naive patients with chronic HCV genotype 1 infection in an open-label, New Zealand Phase IIa trial evaluating oral combinations of AL-335,...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

Odalasvir: Interim Phase IIa data

Achillion reported interim data from 4 cohorts of treatment-naive patients with chronic HCV genotype 1 infection in an open-label, New Zealand Phase IIa trial evaluating oral combinations of AL-335 , odalasvir and Olysio simeprevir. In...
07:00 , Sep 23, 2016 |  BC Extra  |  Clinical News

J&J six-week combo cures all HCV patients in Phase II cohort

All 20 patients receiving a six-week course of a triple-combination therapy from Johnson & Johnson (NYSE:JNJ) to treat HCV genotype 1 infection achieved an SVR12 in a Phase II study, according to J&J's partners Achillion...
08:00 , Feb 29, 2016 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/26 cls Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) Baird Brian Skorney Upgrade Outperform (from neutral) 10% $7.35 Skorney upgraded and maintained his...
07:00 , Oct 26, 2015 |  BC Week In Review  |  Clinical News

AL-335: Phase IIa started

Johnson & Johnson began an open-label Phase IIa trial to evaluate a once-daily oral regimen of Olysio / Sovriad simeprevir, AL-335 and odalasvir ( ACH-3102 ) for 4, 6 or 8 weeks in about 60...